AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Kazia Therapeutics Ltd (ASX:KZA)
Kazia Therapeutics Ltd (ASX:KZA), a biotechnology company that operates in the arena of oncology (cancer), for the first half of FY 19 has reported 56.5% decline in the operating revenue to $28,831. The company for 1H FY 19 has reported a loss after tax of $6,028,195 compared to profit after tax of $424,779 in the prior corresponding period. The companyâs cash balance as at 31 December 2018 fell to $5.4 million from $6.0 million at 30 June 2018. The company had spent $5.8 million for the Research & Development during the period, vs. $9.2 million that was spent in the previous year. However, the company had raised $4.2 million during the period, which will be used for completing phase II GDC-0084 trial, completing the phase I Cantrixil trial and working capital for CY 2020.
Share Price Performance: The shares of KZA have been on a decent uptrend in the recent past. It has delivered a return of 61.76% on a YTD basis. Also, the shares have delivered returns of 50.68% and 20.88% in the past three months and one month respectively. The share price on ASX as of this writing is at $0.550 (as at Fri 15 Mar 19, AEST 04:00 PM) with a 52-week high of $0.800 and 52-week low of $0.330
Telix Pharmaceuticals Ltd (ASX:TLX)
Telix Pharmaceuticals Ltd (ASX:TLX) recently released its 2018 annual report. The trade revenue for 2018 came in at $ 195,142 compared to nil from the previous year. However, on profit/loss from continuing operation front the company reported a loss of $13,829,825 vs. a loss of $6,377,115 in 2017. The loss was driven by increased R&D activities. The R&D costs for 2018 came in at 18,692,034 vs $2,977,062 in 2017. The company for FY18 has posted an R&D tax incentive income of $10,141,969 compared to $403,467 in 2017. On the M&A front, TLX had acquired Advanced Nuclear Medicine Ingredients (ANMI) SA, as part of its strategic investment in prostate cancer imaging. This acquisition will help the company to commercialize illumet prostate imaging (Ga-PSMA) kit for the US market.
Share Price Performance:Â The shares of TLX have been moving up in the past few months and marked a marginal rise on a YTD basis (delivering a return of 5.38%). It has delivered a positive return of 17.09% in the past three months and negative 2.14% in the past one month. The share price on ASX as of this writing is at $0.685 (as at Fri 15 March 2019, AEST 04:00 PM) with a 52-week high of $1.030 and 52-week low of $0.470.
Bionomics Limited (ASX:BNO)
Bionomics Limitedâs (ASX:BNO) stock will be removed from All Ordinaries index, effective from March 18, 2019 due to March 2019 Quarterly Rebalance of the S&P/ASX Indices. Meanwhile, BNO stock has risen by 54.17% in one month as on 14 March 2019 after the company received a positive response of its drug BNC210 for the treatment of PTSD symptoms, as measured by CAPS-5 at 12 weeks. BNC210 Phase 2 trial in Agitation is currently underway in Australia, and the result is expected in the second quarter of CY 2019.
Share Price Performance:Â The shares of BNO have delivered a negative 63.73% in the last six months. However, the share price has bounced back in the previous month, it has zoomed up by 54.17% in one month. The share price on ASX as of this writing is at $0.185 (as at Fri 15 March 2019, AEST 04:00 PM) with a 52-week high of $0.640 and 52-week low of $0.099.
Nanosonics Limited (ASX:NAN)
Strong Financial Performance in 1H FY 19: Nanosonics Limited (ASX:NAN) reported 1HFY19 results recently. For the first half of FY 19 it has reported 36% growth in the total revenue to $40.7 million and 221% growth in profit after income tax to $7.1 million compared to the previous corresponding period. The companyâs cash balance increased by 7% to $71.3 million during 1HFY19 versus PCP, which aid the companyâs ongoing growth and expansion. However, the companyâs free cash flow declined to $1.6 million compared to $3.9 million in PCP. The cash flows during 1H 2019 got affected on the back of rising in an inventory of $3.2 million due to the launch of Trophon 2 in all the major markets and also due to an increase in trade and other receivables of $5.0 million. For FY 19, NAN expects the operating expenses to be approximately $50 million comprised of approximately $12 million in R&D.
Share Price Performance:Â The shares of NAN have been in a decent uptrend in the medium term. It has delivered a YTD returns of 50.0%. It has delivered a return of 34.52% and 18.80% in the past three months and one month respectively. The share price on ASX as of this writing is at $4.170 (as at Fri 15 March 2019, AEST 04:00 PM) with a 52-week high of $4.430 and 52-week low of $2.260.
Imugene Limited (ASX:IMU)
Net Loss Increased in 1H FY 19: Imugene Limited (ASX:IMU) reported total revenues of $1,817,671 for 1H FY19 vs. $719,180 for 1HFY18 translating to an increase of 152.7%. However, the company reported a 111.2% rise in the net loss to $3,449,097. The loss as compared to the comparative period was driven by a substantial rise in a clinical trial and research activities undertaken by the group. Further, the companyâs net assets increased to $31,189,570 versus $15,475,479 as of 30 June 2018, driven by $20.1 million funds raised by the company. As at 31 December 2018, the company had a cash balance of $24,053,140 vs. $7,822,057 as on 30 June 2018.
Share Price Performance:Â The shares of IMU have delivered a negative return of 9.09% in the past six months. However, the shares have bounced up by 17.65% in the past one month. The share price on ASX as of this writing is at $0.020 (as at Fri 15 March 2019, AEST 04:00 PM) with a 52-week high of $0.020.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
